A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. (Q53708013)

18 May 2018

title

A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. (English)

1 reference

18 May 2018

1 reference

10

Kenneth E Truitt

1 reference

18 May 2018

James B Moberly

1

object named as

James B Moberly

1 reference

18 May 2018

author name string

Stuart I Harris

2

1 reference

18 May 2018

Dennis S Riff

3

1 reference

18 May 2018

James Craig Dale

4

1 reference

18 May 2018

Tara Breese

5

1 reference

18 May 2018

Patrick McLaughlin

6

1 reference

18 May 2018

Janet Lawson

7

1 reference

18 May 2018

Yaping Wan

8

1 reference

18 May 2018

Jianbo Xu

9

1 reference

18 May 2018

publication date

10 January 2007

1 reference

18 May 2018

Digestive Diseases and Sciences

published in

1 reference

18 May 2018

volume

52

1 reference

18 May 2018

issue

2

1 reference

18 May 2018

page(s)

442-450

1 reference

18 May 2018

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-006-9521-6

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

12 December 2020

Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats

1 reference

12 December 2020

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Cyclooxygenase inhibition and cardiovascular risk

1 reference

12 December 2020

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers

1 reference

12 December 2020

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

1 reference

12 December 2020

Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo

1 reference

12 December 2020

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

12 December 2020

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

1 reference

12 December 2020

Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor

1 reference

12 December 2020

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

12 December 2020

NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal

1 reference

12 December 2020

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen

1 reference

12 December 2020

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

12 December 2020

An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa

1 reference

12 December 2020

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

12 December 2020

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects

1 reference

12 December 2020

10.1007/S10620-006-9521-6

Identifiers

DOI

1 reference

18 May 2018

1 reference

18 May 2018